Advertisement

Obesity and prostate enlargement in men with localized prostate cancer.

12:32 EDT 22nd May 2013 | BioPortfolio

Summary of "Obesity and prostate enlargement in men with localized prostate cancer."

Study Type - Prevalence (retrospective cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Obesity is associated with prostate enlargement in men without prostate cancer. This study demonstrates an association between obesity and prostate enlargement in men with prostate cancer, and leads to possible implications for prostate cancer screening and diagnosis.
OBJECTIVE:
• To determine if obesity is associated with prostate size in men with prostate cancer. PATIENTS AND
METHODS:
• We examined preoperative body mass index (BMI) and whole prostate weight in a cohort of 16 325 patients undergoing radical prostatectomy for localized prostate cancer from 1975 to 2008 at a single institution. • We used multivariable regression modelling adjusting for age, year of surgery, preoperative serum prostate-specific antigen (PSA), pathological stage and Gleason grade.
RESULTS:
• Of the entire cohort, 13 343 (82%) patients had a prostate weight of at least 40 g. These men were older (P < 0.001), had a higher preoperative BMI (P < 0.002), higher preoperative PSA (P < 0.001), and were more likely to have pT2 disease (P < 0.001). • In multivariable regression, preoperative BMI was associated with increased prostate weight: for each 1 kg/m(2) increase in BMI, prostate weight increased by 0.45 g (95% CI 0.35-0.55, P-trend < 0.001). • Compared with men with BMI < 25 kg/m(2) , men with a BMI ≥35 kg/m(2) had a 40% (odds ratio 1.40, 95% CI 1.01-1.95) increased risk of prostate weight of at least 40 g and a 70% (odds ratio 1.70, 95% CI 1.32-2.20) increased risk of prostate weight of at least 50 g.
CONCLUSIONS:
• In men with localized prostate cancer, obesity is associated with an increased risk of prostate enlargement. • These data validate other observations linking obesity with prostate enlargement and may have important ramifications for prostate cancer diagnosis in obese men.

Affiliation

Division of Urology, Department of Surgery, UC San Diego Medical Center, San Diego, CA The Brady Urological Institute, The Johns Hopkins Medical Institution, Baltimore, MD Department of Surgery, Durham VA Medical Center, Durham, VA Division of Urologic Su

Journal Details

This article was published in the following journal.

Name: BJU international
ISSN: 1464-410X
Pages:

Links

Medical and Biotech [MESH] Definitions

Prostate-specific Antigen

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

Prostatic Secretory Proteins

Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.

Ultrasound, High-intensity Focused, Transrectal

Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).

Transurethral Resection Of Prostate

Removal of all or part of the PROSTATE, often using a cystoscope and/or resectoscope passed through the URETHRA.

Fenretinide

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

PubMed Articles [ 22358 Associated PubMed Articles listed on BioPortfolio]

Association between biomarkers of obesity and risk of high-grade prostatic intraepithelial neoplasia and prostate cancer--evidence of effect modification by prostate size.

Prostate enlargement is common with aging and obesity. We investigated the association between obesity and prostate cancer controlling for differential detection related to prostate enlargement. In an...

Circulating fibroblast-like cells in men with metastatic prostate cancer.

BACKGROUND: Metastatic prostate cancer is an incurable disease. During the development of this disease, prostate cancer cells enter the bloodstream as single cells or clusters of cells. Prostate fibro...

MRI of localized prostate cancer: coming of age in the PSA era.

Prostate cancer is the most common cancer among American men. It varies widely in aggressiveness, ranging from completely indolent to highly aggressive. Currently, predicting the natural history of a...

Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans.

Adiponectin is a protein derived from adipose tissue suspected to have an important role in prostate carcinogenesis. Variants in the adiponectin gene (ADIPOQ) and its type 1 receptor (ADIPOR1) have be...

To screen or not to screen: ongoing debate in the early detection of prostate cancer.

Debate about the use of prostate-specific antigen (PSA) tests to screen prostate cancer in men is ongoing. Prostate cancer is the most common cancer after skin cancer in men and the second most deadly...

Clinical Trials [ 3916 Associated Clinical Trials listed on BioPortfolio]

Study of WST11 in Patients With Localized Prostate Cancer

The aim of this clinical study is to determine the optimal treatment conditions to achieve prostate cancer tumor ablation and to assess the effects of WST11 mediated VTP treatment in patie...

Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer

This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determi...

An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate

Men, 45 years of age or older, with localized prostate cancer will be injected once with a ready made paste including 600 mg 2-hydroxyflutamide (Liproca Depot) into the site of the prostat...

GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer

RATIONALE: Colony-stimulating factors, such as GM-CSF, may help the body build an effective immune response to kill tumor cells. Giving GM-CSF before surgery may be an effective treatment...

R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. R-flurbiprofen may be effective in delaying the recurrence of locali...

Search BioPortfolio: